Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis#
By:
References
- Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942–8.
- Faraone S, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006;36:159–65.
- Faraone SV., Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 2015;1:15020.
- Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011;20:17–37.
- NICE. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. Leicester (UK): British Psychological Society (UK); 2009.
- CADDRA. Canadian ADHD Practice Guidelines (CAP-Guidelines), Third edition. Canadian ADHD Resource Alliance; 2011. Available at: www.caddra.ca.
- AACAP. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894–921.
- Hodgkins P, Sasané R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther 2011;33:188–203.
- Efron D, Davies S, Sciberras E. Current Australian pediatric practice in the assessment and treatment of ADHD. Acad Pediatr 2013;13:328–33.
- Renoux C, Shin J-Y, Dell’Aniello S, Fergusson E, Suissa S. Prescribing trends of attention-deficit hyperactivity disorder (adhd) medications in UK primary care, 1995-2015. Br J Clin Pharmacol 2016;82:858–68.
- Van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: Evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 2009;39:179–95.
- Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009;123:611–6.
- NICE. Attention deficit hyperactivity disorder (ADHD): Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. NICE; 2014. Available at: https://www.nice.org.uk/guidance/cg72.
- FDA. Highlights of prescribing information, Concerta®. 2015. Available at: www.fda.gov; http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021121s015s017lbl.pdf.
- Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 2013;54:227–46.
- Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006;163:1149–52.
- Mosholder A. Psychiatric adverse events in clinical trials of drugs for ADHD. FDA Report PID D060163. US Food and Drug Administration; 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_10_01_Mosholder.pdf.
- Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033.
- Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev 2015;1:CD009885.
- Storebø OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ 2015;351:h5203
- Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies. [in press].
- Higgins J, Green S (Eds.). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. Cochrane Collaboration; 2011. Available at: www.cochrane-www.handbook.org.
- Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group T. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
- Storebø OJ, Rosendal S, Skoog M, Groth C, Bille T, Buch Rasmussen K, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2012;5.
- Storebø OJ, Pedersen N, Ramstad E, Krogh HB, Moreira-Maia CR, Magnusson FL, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents -assessment of harmful effects in non-randomised studies. Cochrane Database Syst Rev 2016;2:CD012069.
- Pelham WE. Pharmacotherapy of children with attention-deficit hyperactivity disorder. School Psychol Rev 1993;22:199–227.
- Gluud L, Thorlund K, Gluud C, Woods L, Harris R, Sterne J. Correction: reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2008;149:219.
- Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982–9.
- Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609–13.
- Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012;157:429–38.
- Savović J, Jones H, Altman D, Harris R, Jűni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 2012;16:1–82.
- Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408–12.
- Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601–5.
- Sterne J, Hernán M, Reeves B, Savović J, Berkman N, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomized studies of interventions. BMJ 2016; 355:i4919.
- Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719–25.
- Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol 2014;14:120.
- Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008;61:763–9.
- Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64–75.
- Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 2017;17:39.
- Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research. 2011. pp. 1–115. Available at: www.ctu.dk/tsa.
- Biostat. Comprehensive meta-analysis [computer program]. Version 2. 2008. Available at: https://www.meta-analysis.com/pages/demo.php.
- The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 2012. Available at: http://community.cochrane.org/tools/review-production-tools/revman-5.
- Inglis SK, Carucci S, Garas P, Hage A, Banaschewski T, Buitelaar JK, et al. Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. BMJ Open 2016;6:e010433.
- Clinicaltrials.gov. NCT02638168, Baweja R. Effects of evening dose of immediate release methylphenidate on sleep in children with ADHD. clinicaltrials.gov. 2015 Dec 18.
- Childress AC, Spencer T, Lopez F, Gerstner O, Thulasiraman A, Muniz R, et al. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:351–61.
- Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Ame Acad Child Adolesc Psychiatry 2008;47:180–8.
- Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham J, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008;47:189–98.
- Green T, Weinberger R, Diamond A, Berant M, Hirschfeld L, Frisch A, et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. J Child Adolesc Psychopharmacol 2011;21:589–95.
- Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry 2011;50:903–14.
- Buitelaar JK, van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. J Child Psychol Psychiatry 1996;37:587–95.
- Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, et al. A comparison of morning-only and morning/late afternoon adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 1999;104:1300–11.
- Pelham WE, Manos MJ, Ezzell CE, Tresco KE, Gnagy EM, Hoffman MT, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005; 44:522–9.
- Schachar R, Ickowicz A, Crosbie J, Donnelly GAE, Reiz JL, Miceli PC, et al. Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008;18:11–24.
- Waxmonsky J, Pelham WE, Gnagy E, Cummings MR, O’Connor B, Majumdar A, et al. The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. J Child Adolesc Psychopharmacol 2008;18:573–88.
- Becker SP, Froehlich TE, Epstein JN. Effects of methylphenidate on sleep functioning in children with attention-deficit/hyperactivity disorder. J Devel Behav Pediatr 2016;37:395–404.
- Froehlich T, Antonini T, Brinkman W, Langberg J, Simon J, Adams R, et al. Mediators of methylphenidate effects on math performance in children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2014;35:100–7.
- Ashkenasi A. Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder. Pediatr Neurol 2011;45:381–6.
- Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BSG, et al. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. J Child Adolesc Psychopharmacol 2015;25:1.
- Baweja R, Belin PJ, Humphrey HH, Babocsai L, Pariseau ME, Waschbusch DA, et al. The effectiveness and tolerability of central nervous system stimulants in school-age children with attention-deficit/hyperactivity disorder and disruptive mood dysregulation disorder across home and school. J Child Adolesc Psychopharmacol 2016;26:154–63.
- Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry 1999;44:811–3.
- Cortese S, Panei P, Arcieri R, Germinario EAP, Capuano A, Margari L, et al. Safety of methylphenidate and atomoxetine in children with attention-deficit/hyperactivity disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs 2015;29:21.
- Didoni A, Sequi M, Panei P, Bonati M, Lombardy ADHD Registry Group T. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. Eur J Clin Pharmacol 2011;67:1061–7.
- Elman I, Sigler M, Kronenberg J, Lindenmayer JP, Doron A, Mendlovic S, et al. Characteristics of patients with schizophrenia successive to childhood attention deficit hyperactivity disorder (ADHD). Isr J Psychiatry Relat Sci 1998;35:280–6.
- Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: A multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Therap 2009;31:1844–55.
- Lee M-S, Lee SI, Hong SD, Kim J-H, Choi J, Joung Y-S. Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: A 12-week multicenter, open-label study. J Child Adolesc Psychopharmacol 2013;23:22–7.
- Na K-S, Lee SI, Hong SD, Kim J-H, Shim S-H, Choi J, et al. Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit/hyperactivity disorder: An open-label study. Int Clin Psychopharmacol 2013;28:184–92.
- MacKenzie LE, Abidi S, Fisher HL, Propper L, Bagnell A, Morash-Conway J, et al. Stimulant medication and psychotic symptoms in offspring of parents with mental illness. Pediatrics 2016;137.
- Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, et al. Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry 2016;6:e956.
- Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: A pilot double-blind randomized trial. J Clin Pharm Ther 2004;29:139–44.
- Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, et al. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. Eur Child Adolesc Psychiatry 2005;14:297–304.
- Hoare P, Remschmidt H, Medori R, Ettrich C, Rothenberger A, Santosh P, et al. 12-Month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 2005;14:305–9.
- Shyu Y-C, Yuan S-S, Lee S-Y, Yang C-J, Yang K-C, Lee T-L, et al. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. Schizophr Res 2015;168:161–7.
- Su Y, Li H, Chen Y, Fang F, Xu T, Lu H, et al. Remission rate and functional outcomes during a 6-month treatment with osmotic-release oral-system methylphenidate in children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2015;35:12.
- Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005;44:1015–23.
- Aguilera-Albesa S, Yoldi-Petri ME, Molins-Castiella T, Dura-Trave T. Hallucinations caused by the introduction of methylphenidate at low doses [Spanish]. Rev Neurologia 2010; 51:254–5.
- Coignoux Y, Estingoy P, Bastard A. From hyperactivity to schizophrenia? Clinical, neurobiological and therapeutic discussion of a case. [French]. Ann Médico-Psychologiques (Paris) 2009:57–65.
- Fernandez-Fernandez MA, Rufo-Campos M, Mateos-Checa R, Munoz-Cabello B, Madruga-Garrido M, Blanco-Martinez B. Childhood psychosis secondary to methylphenidate [Spanish]. Rev Neurologia 2011; 52:446–7.
- Goetz M, Prihodova I, Hrdlicka M. Long lasting complex nocturnal hallucinations during Osmotic Release Oral System (OROS) methylphenidate treatment in a 7-year old girl. Neuroendocrinol Letters 2011;32:619–22.
- Gross-Tsur V, Joseph A, Shalev RS. Hallucinations during methylphenidate therapy. Neurology 2004;63:753–4.
- Halevy A, Shuper A. Methylphenidate induction of complex visual hallucinations. J Child Neurology 2009; 24:1005–7.
- Porfirio MC, Giana G, Giovinazzo S, Curatolo P. Methylphenidate-induced visual hallucinations. Neuropediatrics 2011;42:30–1.
- Rashid J, Mitelman S. Methylphenidate and somatic hallucinations. J Am Acad Child Adolesc Psychiatry 2007;46:945–6.
- Shibib S, Chalhoub N. Stimulant induced psychosis. Child Adolesc Ment Health 2009;14:20–3.
- Tomás Vila M, Izquierdo Quevedo FJ, Cerdán Vera MT, Fernández A, Artés Figueres M, Revert Gomas M. Visual hallucinations caused by methylphenidate [Spanish]. An Pediatr 2010;72:229–30.
- Brown University. Somatic hallucinations with methylphenidate in a 10-year-old boy [Case report]. The Brown University Child & Adolesc Psychopharmacol Update 2007;9:11.
- Irmak A, Ince-Tasdelen B, Ozmen S, Oztop D. Treatment choice in association of attention deficit-hyperactivity disorder with Williams and Moebius Syndromes: Case reports. Klinik Psikofarmakoloji Bülteni 2014;24:226.
- Herguner S, Ozayhan HY. Visual hallucinations with methylphenidate and acetaminophen in combination. J Child Adolesc Psychopharmacol 2015;25:598–9.
- Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 2012;42:1857–63.
- Kelleher I, Harley M, Murtagh A, Cannon M. Are screening instruments valid for psychotic-like experiences? A validation study of screening questions for psychotic-like experiences using in-depth clinical interview. Schizophr Bull 2011;37:362–69.
- Dalsgaard S, Mortensen PB, Frydenberg M, Maibing CM, Nordentoft M, Thomsen PH. Association between attention-deficit hyperactivity disorder in childhood and schizophrenia later in adulthood. Eur Psychiatry 2014;29:259–63.
- Hamshere ML, Stergiakouli E, Langley K, Martin J, Holmans P, Kent L, et al. Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br J Psychiatry 2013;203:107–11.
- Carroll LS, Kendall K, O’Donovan MC, Owen MJ, Williams NM. Evidence that putative ADHD low risk alleles at SNAP25 may increase the risk of schizophrenia. Am J Med Genet Part B Neuropsychiatr Genet 2009;150B:893–9.
- Engert V, Pruessner JC. Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Curr Neuropharmacol 2008;6:322–8.
- Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 2012;3:1–11.
DOI: https://doi.org/10.21307/sjcapp-2018-003 | Journal eISSN: 2245-8875
Language: English
Page range: 52 - 71
Published on: Jul 10, 2018
Published by: Psychiatric Research Unit
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2018 Erica Ramstad, Ole Jakob Storebø, Trine Gerner, Helle B. Krogh, Mathilde Holmskov, Frederik L. Magnusson, Carlos R. Moreira-Maia, Maria Skoog, Camilla Groth, Donna Gillies, Morris Zwi, Richard Kirubakaran, Christian Gluud, Erik Simonsen, published by Psychiatric Research Unit
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.